Search Result

Results for "

cognitive decline

" in MedChemExpress (MCE) Product Catalog:

By Targets:	11β-HSD (4) AMPK (2) Amyloid-β (1) Cholinesterase (ChE) (4) Endogenous Metabolite (2) LPL Receptor (1) Monoamine Oxidase (1) Oxidative Phosphorylation (2)
By Research Areas:	Cancer (2) Cardiovascular Disease (1) Inflammation/Immunology (1) Metabolic Disease (5) Neurological Disease (12)

Inhibitors & Agonists

Inhibitory Antibodies

Natural
Products

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-W106057

11β-HSD1-IN-7	11β-HSD	Neurological Disease Metabolic Disease
11β-HSD1-IN-7 (compound c10a) is a 11β‑HSD1 inhibitor with an IC₅₀ value of 1.9 μM for human 11β‑HSD1. 11β-HSD1-IN-7 can be used for the research of diabetes and cognitive decline .

HY-W129359

11β-HSD1-IN-8	11β-HSD	Neurological Disease Metabolic Disease
11β-HSD1-IN-8 (compound c6a) is a 11β‑HSD1 inhibitor with an IC₅₀ value of 2.3 μM for human 11β‑HSD1. 11β-HSD1-IN-8 can be used for the research of diabetes and cognitive decline .

HY-110291

A-971432	Others	Neurological Disease
A-971432 is a potent, selective and orally active sphingosine-1-phosphate (S1P) receptor 5 agonist with IC₅₀s of .362, >10, 0.006 µM for S1P1, S1P3, S1P5 respectively. A-971432 protects blood–brain barrier (BBB) homeostasis. A-971432 reverses age-related cognitive decline. A-971432 has the potential for the research of alzheimer’s disease or multiple sclerosis .

HY-N5130

Effusol	Others	Neurological Disease
Effusol, a phenolic constituent from Juncus effuses, exhibits potent scavenging activity for DPPH and ABTS radicals, with IC₅₀ values of 79 μM and 2.73 μM, respectively. Effusol rescues CA1 LTP attenuated by corticosterone, defending the hippocampal function against stress-induced cognitive decline .

HY-165514A

Nafimidone hydrochloride	Cholinesterase (ChE)	Neurological Disease
Nafimidone hydrochloride is an anticonvulsant which inhibits cholinesterases, protects neurons, and ameliorates cognitive decline. Nafimidone can be utilized in epilepsy research .

HY-14156

11β-HSD1-IN-15	11β-HSD	Metabolic Disease
11β-HSD1-IN-15 is an inhibitor of 11β-hydroxysteroid dehydrogenase type I (11β-HSD1). 11β-HSD1-IN-15 blocks the conversion of corticosterone to cortisol by binding to the active site of the 11β-HSD1 enzyme. 11β-HSD1-IN-15 can be used to investigate the role of 11β-HSD1 enzymes IN the development of metabolic syndrome, obesity, cognitive decline and type 2 diabetes .

HY-151627

11β-HSD1-IN-11	11β-HSD	Neurological Disease Metabolic Disease
11β-HSD1-IN-11 (Compound c1a) is a competitive 11β-HSD1 inhibitor with IC₅₀s of 0.34 μM and 0.13 μM against rat and human 11β-HSD1, respectively .

HY-113448

CE(20:3(8Z,11Z,14Z)) 20:3 (8Z,11Z,14Z) CE; 20:3 n-6 CE; 20:3 (8Z,11Z,14Z) Cholesterol Ester	Endogenous Metabolite	Cardiovascular Disease
Cholesteryl homo-γ-linolenate is a cholesterol ester. It accumulates in the adrenal gland of rabbits fed a diet high in linolenic acid.1 Levels of cholesteryl homo-γ-linolenate are decreased and positively correlate with cognitive decline in HIV-infected humans.

HY-101339

(R)-RS 56812	Others	Others
(R)-RS 56812 is a 5-HT3 receptor antagonist that enhances performance in monkeys on a delayed matching task. The (R) isomer produces more systematic improvements than the (S) isomer and has potential inhibitory effects in diseases involving cognitive decline.

HY-101339A

(R)-RS 56812 hydrochloride	Others	Others
(R)-RS 56812 hydrochloride is a 5-HT3 receptor antagonist that enhances performance in monkeys on a delayed matching task. The (R) isomer produces more systematic improvements than the (S) isomer and has potential inhibitory effects in diseases involving cognitive decline.

HY-163646

(Rac)-TZ3O	Cholinesterase (ChE)	Neurological Disease
(Rac)-TZ3O is the (Rac) isomer of TZ3O. TZ3O is an anticholinergic compound with neuroprotective activity. TZ3O improves memory impairment and cognitive decline in a scopolamine-induced Alzheimer's disease rat model and can be used in the study of Alzheimer's disease.

HY-155822

TZ3O	Cholinesterase (ChE)	Neurological Disease
TZ3O (compound TZ30) is an anticholinergic agent with neuroprotective effects. TZ3O (2 mg/kg, 4 mg/kg) can improve memory impairment and cognitive decline in rats in the Scopolamine (HY-N0296)-induced Alzheimer-type model. TZ3O could be used in Alzheimer’s research .

HY-P990110

Lecanemab (Mouse IGG2a)	Amyloid-β	Neurological Disease
Lecanemab (Mouse IGG2a) is a monoclonal antibody that targets soluble β-amyloid and has the potential to reduce cognitive decline. The variable region of Lecanemab (Mouse IGG2a) is consistent with that of Lecanemab, while the constant region is of Mouse IGG2a sequence. Lecanemab (Mouse IGG2a) holds promise for research in the field of Alzheimer's disease .

HY-118243

KMS88009	Others	Others
KMS88009 is a potent small molecule that directly interferes with the formation of amyloid-β oligomers, thereby preserving cognitive behavior when used preventively and reversing cognitive behavior decline when used therapeutically. Oral administration of KMS88009 around the onset of Alzheimer's disease symptoms significantly reduced the assembly of amyloid-β oligomers and improved cognitive behavior in the APP/PS1 double transgenic mouse model. This unique dual mode of action suggests that KMS88009 may be a powerful therapeutic candidate for the treatment of Alzheimer's disease. In an evaluation, the physicochemical properties, pharmacokinetics and toxicity of this anti-amyloidogenic small molecule KMS88009 were studied, as well as post-mortem analysis of APP/PS1 TG mice after behavioral testing.

HY-43515

ESI1	Endogenous Metabolite	Metabolic Disease
ESI1 is a small molecule epigenetic silencing inhibitor. ESI1 can trigger the formation of nuclear condensates of key lipid metabolism regulators SREBP1/2, concentrating transcriptional co-activators to drive lipid/cholesterol biosynthesis. ESI1 can promote myelin regeneration in demyelinated animal models and facilitate de novo myelination on regenerating CNS axons, reversing age-related declines in cognitive abilities .

HY-136093A

Lixumistat acetate IM156; HL156A; HL271 acetate	Oxidative Phosphorylation AMPK	Neurological Disease Cancer
Lixumistat (IM156; HL156A; HL271) acetate, a chemical derivative of Metformin (HY-B0627), is a potent and orally active AMPK activator that increases AMPK phosphorylation. Lixumistat (acetate) attenuates aging-associated cognitive impairment in animal model . Lixumistat (acetate) is a potent oxidative phosphorylation (OXPHOS) inhibitor which can be used for the research of solid tumors .

HY-136093

Lixumistat hydrochloride HL271; IM156 hydrochloride; HL156A hydrochloride	Oxidative Phosphorylation AMPK	Neurological Disease Cancer
Lixumistat (HL271) hydrochloride (IM156 hydrochloride; HL156A hydrochloride), a chemical derivative of Metformin (HY-B0627), is a potent AMPK activator that increases AMPK phosphorylation. Lixumistat hydrochloride attenuates aging-associated cognitive impairment in animal model . Lixumistat hydrochloride is a potent oxidative phosphorylation (OXPHOS) inhibitor which can be used for the research of solid tumors .

HY-148115

S1p receptor agonist 2	LPL Receptor	Inflammation/Immunology
S1p receptor agonist 2 (compound 1) is an agonist of S1P5 receptor, exhibits selectivity over the S1P1 and/or S1P3 receptors. S1p receptor agonist 2 can be used for endogenous SIP signaling system research, and alleviating or preventing CNS disorders research, such as neurodegenerative disorders .

HY-158978

Multitarget AD inhibitor-2	Cholinesterase (ChE) Monoamine Oxidase	Neurological Disease
Multitarget AD inhibitor-2 (Compound VN-19) is a multitargeting inhibitor acetylcholinesterase (AChE, IC₅₀=0.14 μM), butyrylcholinesterase (BChE, IC₅₀=11.6 μM), monoamine oxidase B (MAO B, IC₅₀=0.45 μM). Multitarget AD inhibitor-2 inhibits self-induced aggregation of amyloid beta protein Aβ1-42 (inhibition rate is 47.3% at 20 μM), and downregulates the level of ROS in SH-SY5Y (80 inhibition rate at 25 μM). Multitarget AD inhibitor-2 ameliorates the cognitive decline in Scopolamine (HY-N0296)-induced Alzheimer’s Disease zebrafish models .

Cat. No.	Product Name	Target	Research Area

HY-P990110

Lecanemab (Mouse IGG2a)	Amyloid-β	Neurological Disease
Lecanemab (Mouse IGG2a) is a monoclonal antibody that targets soluble β-amyloid and has the potential to reduce cognitive decline. The variable region of Lecanemab (Mouse IGG2a) is consistent with that of Lecanemab, while the constant region is of Mouse IGG2a sequence. Lecanemab (Mouse IGG2a) holds promise for research in the field of Alzheimer's disease .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N5130

Effusol	Juncus effusus Linn. Juncaceae Source classification Phenols Polyphenols Plants	Others
Effusol, a phenolic constituent from Juncus effuses, exhibits potent scavenging activity for DPPH and ABTS radicals, with IC₅₀ values of 79 μM and 2.73 μM, respectively. Effusol rescues CA1 LTP attenuated by corticosterone, defending the hippocampal function against stress-induced cognitive decline .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.

cognitive decline

Inhibitors & Agonists

Inhibitory Antibodies

NaturalProducts

Natural
Products